Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Global, Phase III, Double Blind, Randomized Controlled Study to Compare the Efficacy, Safety & Immunogenicity of LUBT010 With Lucentis® in Patients With Neovascular Age Related Macular Degeneration

NCT04690556 is registered in ClinicalTrials.gov with Lupin Ltd. as lead sponsor.

NCT NCT04690556
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04690556 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Global, Phase III, Double Blind, Randomized Controlled Study to Compare the Efficacy, Safety & Immunogenicity of LUBT010 With Lucentis® in Patients With Neovascular Age Related Macular Degeneration
Lead sponsor
Lupin Ltd.
Phase
Phase 3
Overall status
Completed
Start date
September 14, 2020
Completion date
May 31, 2024
Enrollment
600 (actual)
Sites
78

Conditions

As the registry lists them; a condition with its own page is linked.

neovascular age-related macular degeneration